Hanmi Science Co Ltd
KRX:008930
Hanmi Science Co Ltd
KRX:008930
Price:
29 050
KRW
-0.34%
Market Closed
Market Cap:
2T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Hanmi Science Co Ltd
29050
-100 (-0.34%)
| 52 Week Range |
26 750
56 200
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Hanmi Science Co Ltd
Balance Sheet
Balance Sheet Decomposition
Hanmi Science Co Ltd
Hanmi Science Co Ltd
| Current Assets | 286.8B |
| Cash & Short-Term Investments | 53.6B |
| Receivables | 97.4B |
| Other Current Assets | 135.9B |
| Non-Current Assets | 1T |
| Long-Term Investments | 833.5B |
| PP&E | 98.3B |
| Intangibles | 65.6B |
| Other Non-Current Assets | 16.6B |
| Current Liabilities | 426.8B |
| Accounts Payable | 81.6B |
| Accrued Liabilities | 10.4B |
| Short-Term Debt | 202.5B |
| Other Current Liabilities | 132.3B |
| Non-Current Liabilities | 33.5B |
| Long-Term Debt | 1.5B |
| Other Non-Current Liabilities | 32B |
Balance Sheet
Hanmi Science Co Ltd
Hanmi Science Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
22 047
|
94 392
|
102 546
|
38 360
|
26 858
|
16 747
|
14 849
|
16 591
|
21 421
|
27 579
|
|
| Cash Equivalents |
22 047
|
94 392
|
102 546
|
38 360
|
26 858
|
16 747
|
14 849
|
16 591
|
21 421
|
27 579
|
|
| Short-Term Investments |
0
|
0
|
0
|
5 485
|
0
|
0
|
0
|
0
|
0
|
6 000
|
|
| Total Receivables |
125 572
|
240 160
|
127 316
|
107 549
|
101 417
|
91 092
|
87 903
|
94 216
|
110 550
|
108 771
|
|
| Accounts Receivables |
89 323
|
239 841
|
124 851
|
106 216
|
100 590
|
90 725
|
86 614
|
93 520
|
109 474
|
107 055
|
|
| Other Receivables |
36 249
|
319
|
2 465
|
1 333
|
827
|
367
|
1 289
|
696
|
1 076
|
1 716
|
|
| Inventory |
114 958
|
92 576
|
95 667
|
107 709
|
102 819
|
100 883
|
110 186
|
105 971
|
112 229
|
104 869
|
|
| Other Current Assets |
8 550
|
3 264
|
4 464
|
2 154
|
13 363
|
8 357
|
2 789
|
5 781
|
1 149
|
26 682
|
|
| Total Current Assets |
271 127
|
430 393
|
329 993
|
261 258
|
244 457
|
217 079
|
215 727
|
222 559
|
245 348
|
273 900
|
|
| PP&E Net |
23 503
|
24 823
|
27 750
|
27 054
|
25 718
|
26 341
|
25 641
|
26 044
|
88 919
|
94 068
|
|
| PP&E Gross |
23 503
|
24 823
|
27 750
|
27 054
|
25 718
|
26 341
|
25 641
|
26 044
|
88 919
|
94 068
|
|
| Accumulated Depreciation |
3 949
|
4 358
|
5 412
|
7 233
|
8 927
|
13 379
|
16 521
|
14 187
|
16 218
|
20 794
|
|
| Intangible Assets |
5 176
|
7 189
|
8 473
|
12 548
|
11 181
|
10 411
|
8 815
|
7 583
|
19 127
|
67 138
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
1 470
|
826
|
370
|
634
|
559
|
|
| Long-Term Investments |
441 340
|
460 878
|
593 827
|
630 695
|
625 925
|
645 691
|
657 542
|
679 990
|
743 077
|
775 356
|
|
| Other Long-Term Assets |
1 650
|
8 742
|
9 206
|
7 229
|
9 265
|
9 840
|
14 669
|
13 348
|
12 586
|
15 148
|
|
| Total Assets |
742 795
N/A
|
932 024
+25%
|
969 249
+4%
|
938 783
-3%
|
916 546
-2%
|
910 832
-1%
|
923 220
+1%
|
949 894
+3%
|
1 109 691
+17%
|
1 226 170
+10%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
213 447
|
211 395
|
197 398
|
176 923
|
153 550
|
130 912
|
123 932
|
104 568
|
77 557
|
59 842
|
|
| Accrued Liabilities |
3 165
|
16 255
|
4 563
|
4 920
|
6 243
|
6 411
|
6 161
|
9 142
|
11 598
|
13 195
|
|
| Short-Term Debt |
70 000
|
40 000
|
25 000
|
25 000
|
20 000
|
44 000
|
45 000
|
50 000
|
191 250
|
200 850
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1 125
|
1 155
|
6 293
|
4 270
|
10 511
|
|
| Other Current Liabilities |
29 733
|
69 459
|
77 754
|
37 746
|
47 429
|
45 740
|
43 865
|
50 992
|
63 051
|
110 805
|
|
| Total Current Liabilities |
316 345
|
337 109
|
304 715
|
244 590
|
227 222
|
228 188
|
220 113
|
220 995
|
347 726
|
395 202
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
298
|
5 275
|
201
|
6 483
|
10 769
|
|
| Deferred Income Tax |
2 426
|
1 981
|
5 262
|
4 712
|
4 488
|
872
|
959
|
286
|
5 836
|
12 483
|
|
| Minority Interest |
1 656
|
569
|
2 277
|
2
|
0
|
1
|
2
|
3
|
2
|
34
|
|
| Other Liabilities |
6 312
|
8 685
|
11 708
|
24 329
|
31 742
|
35 787
|
38 139
|
38 117
|
24 898
|
20 244
|
|
| Total Liabilities |
326 740
N/A
|
348 344
+7%
|
323 962
-7%
|
273 629
-16%
|
263 452
-4%
|
265 147
+1%
|
264 484
0%
|
259 596
-2%
|
384 945
+48%
|
438 663
+14%
|
|
| Equity | |||||||||||
| Common Stock |
27 277
|
28 593
|
29 145
|
31 140
|
31 750
|
32 371
|
33 006
|
33 652
|
34 312
|
34 978
|
|
| Retained Earnings |
169 090
|
344 570
|
323 940
|
350 948
|
342 865
|
355 946
|
367 923
|
397 060
|
461 188
|
533 274
|
|
| Additional Paid In Capital |
228 782
|
211 349
|
299 043
|
230 571
|
230 191
|
229 570
|
228 936
|
228 289
|
227 629
|
226 963
|
|
| Unrealized Security Profit/Loss |
6 993
|
0
|
6 533
|
6 162
|
9 312
|
29 352
|
28 013
|
25 786
|
35 012
|
36 578
|
|
| Treasury Stock |
18 577
|
0
|
0
|
14 336
|
15 334
|
15 982
|
16 330
|
17 344
|
37 100
|
44 925
|
|
| Other Equity |
2 490
|
831
|
309
|
72 993
|
72 934
|
73 133
|
73 214
|
74 427
|
73 729
|
73 794
|
|
| Total Equity |
416 055
N/A
|
583 681
+40%
|
645 287
+11%
|
665 154
+3%
|
653 093
-2%
|
645 686
-1%
|
658 736
+2%
|
690 298
+5%
|
724 746
+5%
|
787 507
+9%
|
|
| Total Liabilities & Equity |
742 795
N/A
|
932 024
+25%
|
969 249
+4%
|
938 783
-3%
|
916 546
-2%
|
910 832
-1%
|
923 220
+1%
|
949 894
+3%
|
1 109 691
+17%
|
1 226 170
+10%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
65
|
64
|
66
|
65
|
66
|
66
|
66
|
67
|
67
|
68
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
